Singapore - Aiming to create the Biopolis of Asia

In December 2006, Vinnova was assigned by the Swedish government to conduct an international benchmarking of the Swedish sectorial innovation systems in pharmaceuticals, biotechnology and medical technology. Case studies and international comparisons of different countries are important in assessing and understanding the Swedish conditions for life science research and innovation. It was decided to carry out a case study on Singapore since during the last decade the country has invested heavily in research and development in the biomedical field and achieved striking results both scientifically and in attracting industrial investment.

This study is based on data and information concerning policy, industry and science and addresses the trends and performance of the Singaporean Life Science innovation system. Literature and bibliometric studies as well as interviews have been used for the analysis. Accordingly, representatives of governmental bodies, venture capital firms, universities, and large and small life science companies have been interviewed.